Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. saw a notable rise in stock performance on November 24, 2025, with significant gains over the past week and month. Despite strong year-to-date growth, the company faces challenges such as negative EBITDA and a high price-to-book ratio, reflecting a complex financial situation.

Arrowhead Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant growth over the past year, despite being in a loss-making position and not offering dividends, indicating a focus on reinvestment and expansion.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 43.69 on October 31, 2025, reflecting strong growth in the Pharmaceuticals & Biotechnology industry. Despite its loss-making status and challenges in profitability, the company has shown significant performance improvement over the past year, outpacing broader market gains.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 43.33 on October 30, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen a 72.62% growth over the past year, despite being loss-making, and has a market capitalization of USD 3,756 million.

Arrowhead Pharmaceuticals has achieved a new 52-week high of USD 40.74, significantly up from its low of USD 9.57. The company, with a market cap of approximately USD 3,756 million, has seen a 64.38% stock increase over the past year, despite ongoing financial losses and a premium valuation.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 39.42 on October 6, 2025, reflecting a 53.0% increase over the past year. With a market capitalization of USD 3,756 million, the company remains in a loss-making position, highlighting its unique financial structure within the biotechnology sector.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 36.24 on October 3, 2025, reflecting a substantial increase over the past year. With a market capitalization of USD 3,756 million, the company remains in a loss-making position, indicated by its financial metrics and premium valuation.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 35.40 on October 1, 2025, reflecting strong performance in the Pharmaceuticals and Biotechnology sector. The company has seen a 42.84% growth over the past year, significantly outperforming the S&P 500, despite being loss-making.

Arrowhead Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting a strong performance over the past year. The company, with a market capitalization of USD 3,756 million, is noted for its innovative approaches in the biotech sector, despite its current loss-making status and complex financial metrics.

Arrowhead Pharmaceuticals, Inc. has seen a notable rise in its stock today, reaching an intraday high. Over the past week and month, the company has significantly outperformed the S&P 500. However, its long-term performance remains challenged, with a decline over the past five years.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 33.73 on September 24, 2025, reflecting a significant performance improvement from its previous low. With a market capitalization of USD 3,756 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite facing financial challenges.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 33.00 on September 23, 2025, reflecting strong performance over the past year with a 32.6% increase. The company, categorized as a small-cap stock, operates in the Pharmaceuticals & Biotechnology industry and has a market capitalization of approximately USD 3,756 million.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 32.17 on September 22, 2025, reflecting a strong performance over the past year. Despite being loss-making, the company has a market capitalization of USD 3,756 million and continues to navigate the competitive pharmaceuticals and biotechnology sector.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 31.67 on September 19, 2025, highlighting its strong performance in the Pharmaceuticals & Biotechnology sector. Despite being loss-making, the company has shown a 25.21% increase over the past year, surpassing the S&P 500's gains.

Arrowhead Pharmaceuticals, Inc. has seen notable stock activity today, rising significantly amid a slight decline in the S&P 500. The company has shown impressive short-term gains, outperforming the index over the past month and year-to-date, but faces long-term challenges with negative EBITDA and a declining five-year performance.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 31.62 on September 18, 2025, reflecting a strong performance over the past year. With a market capitalization of USD 3,756 million, the company continues to navigate challenges in the Pharmaceuticals & Biotechnology sector despite its current loss-making status.